These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32387834)

  • 1. History of risedronate.
    McClung MR; Ebetino FH
    Bone; 2020 Aug; 137():115407. PubMed ID: 32387834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
    McClung MR; Miller PD; Brown JP; Zanchetta J; Bolognese MA; Benhamou CL; Balske A; Burgio DE; Sarley J; McCullough LK; Recker RR
    Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
    McClung MR; Balske A; Burgio DE; Wenderoth D; Recker RR
    Osteoporos Int; 2013 Jan; 24(1):301-10. PubMed ID: 23079690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
    Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
    Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of alendronate and risedronate in preventing and treating osteoporosis.
    Peters ML; Leonard M; Licata AA
    Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
    Moro-Alvarez MJ; Díaz-Curiel M
    Clin Interv Aging; 2008; 3(2):227-32. PubMed ID: 18686745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI; Bonnick SL; Kagan R; Thompson DE; Skalky CS; Chen E; de Papp AE;
    Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
    Emkey R
    MedGenMed; 2004 Jul; 6(3):6. PubMed ID: 15520628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
    Thomasius F; Palacios S; Alam A; Boolell M; Vekeman F; Gauthier G
    Osteoporos Int; 2022 Jan; 33(1):217-228. PubMed ID: 34490504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J; Takeda T; Sato Y
    Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.